We are live on ! Find out more
APM

Avidity Partners Management Portfolio holdings

AUM $936M
1-Year Est. Return 195%
This Fund
S&P 500
This Quarter Est. Return
-2.03%
1 Year Est. Return
+195%
3 Year Est. Return
+460.87%
5 Year Est. Return
+815.5%
10 Year Est. Return
–
AUM
$2.48B
AUM Growth
-$380M
Cap. Flow
-$210M
Cap. Flow %
-8.45%
Top 10 Hldgs %
29.58%
Holding
106
New
13
Increased
24
Reduced
44
Closed
23

Top Buys

Rank Stock Value
1
BSX icon
Boston Scientific
BSX
+$67.1M
2
CI icon
Cigna
CI
+$59.2M
3
UNH icon
UnitedHealth
UNH
+$55.2M
4
HUM icon
Humana
HUM
+$51.8M
5
ITCI
Intra-Cellular Therapies Inc.
ITCI
+$46.7M

Top Sells

Rank Stock Value
1
GEHC icon
GE HealthCare
GEHC
+$84.9M
2
ABBV icon
AbbVie
ABBV
+$69.8M
3
BIO icon
Bio-Rad Laboratories Class A
BIO
+$57.9M
4
COR icon
Cencora
COR
+$57.7M
5
ARGX icon
argenx
ARGX
+$50.7M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARGX icon
26
argenx
ARGX
$55.6B
$39.6M 1.6%
80,600
-103,700
-56% -$50.7M
SGRY icon
27
Surgery Partners
SGRY
$1.98B
$39.1M 1.58%
1,338,000
-217,000
-14% -$7.8M
LNTH icon
28
Lantheus
LNTH
$7.03B
$38.8M 1.56%
558,400
+313,300
+128% +$22.9M
PCVX icon
29
Vaxcyte
PCVX
$8.01B
$38.5M 1.55%
756,165
-118,835
-14% -$5.86M
BPMC
30
DELISTED
Blueprint Medicines
BPMC
$37.7M 1.52%
751,600
+336,600
+81% +$18M
AKRO
31
DELISTED
Akero Therapeutics
AKRO
$37.4M 1.51%
739,100
-285,900
-28% -$13.3M
MIRM icon
32
Mirum Pharmaceuticals
MIRM
$6.96B
$36.1M 1.45%
+1,142,850
New +$31.3M
PRVA icon
33
Privia Health
PRVA
$3.11B
$35.5M 1.43%
1,545,100
+465,294
+43% +$11.8M
DXCM icon
34
DexCom
DXCM
$28.3B
$35.2M 1.42%
+377,700
New +$42.6M
BHVN icon
35
Biohaven
BHVN
$2.18B
$33.4M 1.35%
1,285,400
-39,600
-3% -$823K
RCKT icon
36
Rocket Pharmaceuticals
RCKT
$355M
$32.5M 1.31%
1,587,429
+261,429
+20% +$4.75M
AMLX icon
37
Amylyx Pharmaceuticals
AMLX
$2.17B
$32.2M 1.3%
1,756,940
+855,540
+95% +$18.1M
IMGN
38
DELISTED
Immunogen Inc
IMGN
$30.4M 1.23%
1,917,907
-79,893
-4% -$1.33M
BIIB icon
39
Biogen
BIIB
$29.5B
$29.7M 1.19%
115,400
-58,600
-34% -$15.7M
CRBU icon
40
Caribou Biosciences
CRBU
$158M
$28.9M 1.16%
6,050,212
+3,291,612
+119% +$20.4M
ARWR icon
41
Arrowhead Research
ARWR
$12B
$28.6M 1.15%
1,063,897
+138,897
+15% +$4.25M
HCA icon
42
HCA Healthcare
HCA
$86.4B
$28.2M 1.14%
+114,800
New +$31.4M
NMRA icon
43
Neumora Therapeutics
NMRA
$308M
$25.4M 1.02%
+1,800,000
New +$22.5M
GPCR icon
44
Structure Therapeutics
GPCR
$3.46B
$25.2M 1.02%
500,000
+462,200
+1,223% +$14.9M
UHS icon
45
Universal Health Services
UHS
$9.64B
$22.9M 0.92%
182,000
-188,100
-51% -$25.7M
CVAC
46
DELISTED
CureVac
CVAC
$21.3M 0.86%
3,116,100
-1,183,900
-28% -$10.5M
AXSM icon
47
Axsome Therapeutics
AXSM
$12.3B
$20.7M 0.84%
296,800
-248,200
-46% -$18.6M
RARE icon
48
Ultragenyx Pharmaceutical
RARE
$2.65B
$19.4M 0.78%
544,000
-356,700
-40% -$14.1M
PRTA icon
49
Prothena Corp
PRTA
$455M
$18.4M 0.74%
382,305
-152,695
-29% -$9.07M
RVMD icon
50
Revolution Medicines
RVMD
$40B
$18.2M 0.73%
657,200
-417,800
-39% -$12.4M
1
2
3 4 5

Similar funds

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
PWAM
Private Wealth Asset Management Cedar Rapids, Iowa $935M AUM 17.66% 1-Year Est. Return
LJAC
L.J. Altfest & Co New York $935M AUM 27.19% 1-Year Est. Return
NI
NetEase Inc Hangzhou, China $934M AUM 11.31% 1-Year Est. Return
MCM
Massar Capital Management Stamford, Connecticut $934M AUM 14.18% 1-Year Est. Return
TS
Tamar Securities Woodland Hills, California $934M AUM 26.74% 1-Year Est. Return
TW
TritonPoint Wealth Chevy Chase, Maryland $934M AUM 23.95% 1-Year Est. Return
PGA
Portland Global Advisors Portland, Maine $938M AUM 13.22% 1-Year Est. Return

Avidity Partners Management's Q3 2023 Portfolio in Review

As of Q3 2023, Avidity Partners Management held 106 positions worth $2.48B, down 13% from $2.86B the previous quarter. Its ten largest holdings account for 30% of the portfolio.

Avidity Partners Management withdrew a net $210M in Q3 2023, closing 23 positions and reducing 44 holdings. Its most notable exit was GE HealthCare, an estimated $84.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Technology.

Against the trend, Avidity Partners Management opened a new position in Cigna worth $59.4M.

  • Avidity Partners Management's largest Q3 2023 buy was Cigna: 207,700 shares worth $59.4M.
  • Avidity Partners Management added most to Boston Scientific in Q3 2023, an estimated $67.1M increase.
  • Avidity Partners Management's biggest Q3 2023 reduction was argenx, cutting an estimated $50.7M.
  • Avidity Partners Management fully exited GE HealthCare in Q3 2023, selling an estimated $84.9M.
  • Avidity Partners Management's ten largest holdings make up 30% of its $2.48B portfolio in Q3 2023.
  • Avidity Partners Management opened 13 new positions and closed 23 in Q3 2023.
  • Avidity Partners Management's portfolio value fell 13% quarter-over-quarter to $2.48B.

Based on Avidity Partners Management's 13F filing for Q3 2023, filed 14 Nov 2023.